Solara Active Pharma Sciences consolidated Q1FY26 PAT rises to Rs. 10.52 Cr

Solara Active Pharma Sciences has reported total income of Rs. 320.13 crores during the period ended June 30, 2025

RPG Life Sciences Q1 FY2026 PAT slips to Rs. 26.29 Cr

RPG Life Sciences has reported total income of Rs. 174.15 crores during the period ended June 30, 2025

SMS Lifesciences India receives EIR with VAI status from USFDA for API facility at Kazipally

The receipt of EIR reaffirms the company's commitment to maintaining global quality standards

Suven Life Sciences announces first patient randomized in Phase-2b clinical trial of Ropanicant

There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated

Waters, BD biosciences unit agree to $17.5 billion merger

The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026

Hexaware and Abluva join forces to deliver secure Agentic AI solutions for life sciences industry

This collaboration marks a significant milestone for Abluva as the company aims to deliver value and innovative solutions in agentic AI security

IMCD opens life science laboratory hub in Shanghai

The pharmaceuticals laboratory supports North Asia with formulation development, reverse engineering, troubleshooting, and analysis for various dosage forms

AB Science receives FDA and EMA authorization for phase 3 Trial of prostate cancer treatment

Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments

Nectar Lifesciences sell API and formulations business to Ceph Lifesciences for Rs. 1,270 Cr

Shilpa Pharma Lifesciences Unit-1 inspected by ANVISA

The audit has been concluded with no major observations